📖 Module 17 of 17 — Reference
Expert
Vocabulary Glossary
75 key terms across every FDA-regulated category — defined with precision, cited with CFR references where applicable, and organized for quick lookup. Use the search box to find any term instantly, or browse by letter. This is the reference you keep open during every client engagement.
Knowledge Hub Complete
You've reached the final module. All 17 modules of the Orionex FDA Knowledge Hub are now available. You have the complete FDA regulatory framework — from foundational law to practical import operations — that makes an expert consultant.
Apply This Knowledge with a Client →
75 terms
A
Abbreviated New Drug ApplicationANDA21 CFR Part 314Drug
The application pathway for generic drugs. An ANDA demonstrates that the generic product is pharmaceutically equivalent and bioequivalent to a Reference Listed Drug (RLD) approved through an NDA. No new clinical trials required — the applicant relies on the innovator's safety and efficacy data. Approved ANDAs appear in the Orange Book with therapeutic equivalence ratings.
ALCOA+GMP
The data integrity standard for all FDA-regulated manufacturing records. Attributable (signed by person who performed the activity), Legible (readable permanently), Contemporaneous (recorded at time of activity), Original (first record of data), Accurate (true and error-free). The '+' adds: Complete, Consistent, Enduring, Available. ALCOA+ violations are treated as potential fraud, not merely quality deficiencies.
Adulteration21 U.S.C. §§ 342, 351, 361General
A product is adulterated if it is unsafe, filthy, manufactured under insanitary conditions, or below required quality. Adulteration is a strict liability offense — intent is not required for a misdemeanor conviction. Products from unregistered facilities are automatically adulterated under 21 U.S.C. § 342(j) (food) and § 351(a)(2)(B) (drugs).
Adverse EventAEPost-Market
Any undesirable experience associated with a regulated product. For drugs and biologics: an unintended response to a drug at any dose. For devices: a malfunction, injury, or death associated with device use. For dietary supplements: any harm associated with supplement use. Serious adverse events (hospitalization, death, disability) trigger mandatory reporting obligations within defined timeframes.
Annual Product ReviewAPR21 CFR § 211.180(e)Drug/Device
A comprehensive annual review of each drug product manufactured, covering batch records, complaints, returns, stability data, and process validation status. Required for drug manufacturers under cGMP. Also called Product Quality Review (PQR). For PMA devices: annual reports required within 30 days of the anniversary of approval.
B
BioequivalenceBE21 CFR Part 320Drug
Demonstration that a generic drug product performs in the body in the same way as the Reference Listed Drug. Standard: the 90% confidence interval for AUC and Cmax ratios must fall within 80–125% of the RLD values. Bioequivalence is the foundational requirement for ANDA approval. Narrow therapeutic index drugs may require tighter BE criteria.
Biologic License ApplicationBLA21 CFR Part 601Biologic
The approval pathway for biological products under Section 351 of the Public Health Service (PHS) Act. Unlike an NDA, a BLA licenses both the product AND the specific manufacturing facility — changing the manufacturing site requires a Prior Approval Supplement. The BLA is reviewed by either CBER (vaccines, blood, gene/cell therapy, allergenics) or CDER (therapeutic proteins, monoclonal antibodies).
Biosimilar42 U.S.C. § 262(k)Biologic
A biological product that is highly similar to and has no clinically meaningful differences from an approved reference biologic in terms of safety, purity, and potency. Approved under Section 351(k) of the PHS Act. Distinguished from a generic drug (identical to the reference) because biologics cannot be exactly copied — their structure depends on the manufacturing process.
Bioterrorism Act21 U.S.C. §§ 350b–350dFood
The Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Created mandatory food facility registration with FDA for the first time in U.S. history. Established the Prior Notice requirement for all food imports. Gave FDA authority to administratively detain food believed to pose a threat to public health.
C
CAPACAPA21 CFR § 820.100GMP
Corrective and Preventive Action. A formal quality system process for identifying, investigating, and eliminating quality problems. Corrective action addresses existing problems (fixing what went wrong). Preventive action addresses potential problems (preventing what could go wrong). CAPA records are among the first documents FDA investigators request during any GMP inspection.
Certificate of AnalysisCoAGMP
A document provided by a supplier or testing laboratory confirming that a specific lot of material meets established specifications for identity, purity, potency, and other quality parameters. For dietary supplements, a supplier's CoA alone does not satisfy the identity testing requirement under 21 CFR § 111.75 — independent testing must still be performed.
cGMPcGMPGMP
Current Good Manufacturing Practice. The 'current' designation means manufacturers must use up-to-date technology and systems — complying with the regulations as they are today, not as they were when the facility was built. FDA's position: what constitutes 'current' evolves with advances in science and technology, and FDA can cite manufacturers for using outdated practices even if those practices were acceptable when originally implemented.
Consent DecreeEnforcement
A court-approved agreement between FDA/DOJ and a regulated company that resolves an injunction action. The company agrees to specific corrective actions, timelines, independent oversight, and financial penalties for non-compliance. Consent decrees are permanent court orders — violating them constitutes contempt of court. Companies under consent decrees typically bear significant ongoing costs including third-party expert oversight at $50,000–$100,000/month.
Cosmetics DirectCosmetics
FDA's online portal for cosmetic facility registration and product listing under MoCRA. Accessible at cosmeticsdirect.fda.gov. Separate from FURLS (food/device) and DRLS (drugs). Both facility registration (deadline December 29, 2023) and product listing (deadline July 1, 2024) are completed through Cosmetics Direct.
D
DSHEADSHEA21 U.S.C. §§ 321(ff), 350bSupplement
Dietary Supplement Health and Education Act of 1994. Created the regulatory framework for dietary supplements as a distinct product category — distinct from both food and drugs. Key provisions: no pre-market approval required, allows structure/function claims with a required disclaimer, shifts burden of proof to FDA to demonstrate a supplement is unsafe before removing it from the market. NDI notification required for ingredients not marketed before October 15, 1994.
Data IntegrityGMP
The completeness, consistency, and accuracy of data throughout its lifecycle. FDA's data integrity expectations are captured in the ALCOA+ framework. Data integrity failures — deleted audit trails, backdated records, test-fail-discard-retest without documentation — are treated as fraud, not merely quality deficiencies, and have resulted in criminal prosecution of pharmaceutical company executives.
De Novo Classification21 U.S.C. § 360c(f)(2)Device
A regulatory pathway for novel, low-to-moderate risk medical devices that have no valid predicate for a 510(k) submission. De Novo creates a new device type and issues a classification order authorizing marketing. Once classified through De Novo, the device can serve as a predicate for future 510(k) submissions. Fee similar to 510(k); 150-day review clock.
Detention Without Physical ExaminationDWPEImport
The operational mode of an import alert — FDA instructs CBP to detain products from a listed facility, product, or country-product combination without physically examining each shipment. The most severe import enforcement tool. DWPE can be lifted for food/cosmetic products through private laboratory testing; for drug/device products, typically requires an FDA re-inspection with clean results.
Drug Establishment Registration21 CFR Part 207Drug
Annual registration required for every domestic and foreign establishment that manufactures, repackages, or relabels drugs for the U.S. market. Filed through the Drug Registration and Listing System (DRLS) using Structured Product Labeling (SPL) XML format. Annual fees apply under GDUFA (generic drug establishments) and PDUFA (branded drug establishments). Foreign establishments: ~$75,000/year. Renewal window: October 1 – December 31.
E
eSTARDevice
Electronic Submission Template and Resource. The standardized electronic submission format required by CDRH for all 510(k) submissions since October 2022. eSTAR is a structured template that guides applicants through all required sections of a 510(k) submission. Submissions not using eSTAR format are not accepted by CDRH.
Establishment Inspection ReportEIRInspection
A comprehensive narrative report prepared by an FDA investigator after completing a facility inspection. The EIR documents everything that occurred during the inspection — observations, records reviewed, samples collected, verbal responses by facility personnel, and the investigator's recommended classification (NAI, VAI, or OAI). EIRs are released to the public under FOIA after enforcement action is resolved.
F
FD&C Act21 U.S.C. §§ 301–399dGeneral
The Federal Food, Drug, and Cosmetic Act of 1938. The foundational statute governing FDA regulation of food, drugs, devices, and cosmetics. Introduced the requirements for drug safety demonstration before marketing. Created the concepts of adulteration and misbranding. Established FDA's inspection authority. Has been amended dozens of times since 1938, most recently by MoCRA (2022).
FEI NumberFood
Food Establishment Identifier. A permanent 7–8 digit number assigned by FDA to each food facility upon registration. Required on all Prior Notice filings, FDA inspections, and import entries. The FEI number stays with the facility permanently — it does not change with ownership changes. Foreign food manufacturers must provide their FEI to their U.S. customs broker for every shipment.
Form 48348321 CFR § 2.7Inspection
Inspectional Observations. The written list of conditions observed during an FDA inspection that the investigator believes may constitute violations of the FD&C Act. Issued at the closeout meeting at the end of an inspection. Not a final determination of violation — facilities have the right and opportunity to respond within 15 business days. Form 483s are public documents released under FOIA.
FSMAFSMA21 U.S.C. §§ 2201–2252Food
Food Safety Modernization Act of 2011. The most sweeping food safety reform in 70 years. Shifted FDA's approach from reactive (responding to outbreaks) to preventive (requiring hazard analysis and preventive controls). Seven major rules: Preventive Controls for Human Food (21 CFR 117), Animal Food (21 CFR 507), Produce Safety Rule (21 CFR 112), FSVP (21 CFR Part 1 Subpart L), Intentional Adulteration (21 CFR 121), Sanitary Transportation (21 CFR Part 1 Subpart O), and Third-Party Certification.
FSVPFSVP21 CFR Part 1, Subpart LFood
Foreign Supplier Verification Program. An FSMA rule that places legal responsibility on U.S. food importers to verify that their foreign suppliers produce food meeting U.S. safety standards. The FSVP obligation is on the U.S. importer, not the foreign supplier — but foreign suppliers must cooperate by providing documentation (food safety plan summaries, audit reports, testing records). FSVP is one of the most significant consulting service opportunities created by FSMA.
G
GRASGRAS21 U.S.C. § 321(s)Food
Generally Recognized as Safe. An ingredient is GRAS if it is recognized as safe by qualified experts based on either scientific procedures or a history of safe use before 1958. GRAS status can be established through FDA affirmation (listed in 21 CFR Parts 182–186), GRAS notification (company submits safety evidence; FDA responds with no objection), or self-affirmation (company determines GRAS status internally without notifying FDA). Substances not GRAS must be approved as food additives before use.
GUDIDDevice
Global Unique Device Identification Database. FDA's publicly accessible database of device identifiers (DI) submitted by device manufacturers. Every device subject to UDI requirements must have its DI submitted to GUDID before distribution. The public can search GUDID to look up any registered device's name, manufacturer, version/model, sterility, and other characteristics. Hospitals and healthcare facilities use GUDID for device tracking and adverse event reporting.
H
HARPCHARPC21 CFR Part 117Food
Hazard Analysis and Risk-Based Preventive Controls. FSMA's preventive controls framework for human food — the U.S. regulatory equivalent of HACCP but broader. HARPC requires: hazard analysis identifying all significant biological, chemical, physical, and radiological hazards (including economically motivated adulteration); preventive controls to address each significant hazard; monitoring procedures; corrective actions; verification; and a recall plan. Must be developed and signed by a PCQI.
Hatch-Waxman Act21 U.S.C. §§ 355(j), 271(e)Drug
The Drug Price Competition and Patent Term Restoration Act of 1984. Created the ANDA pathway for generic drugs, allowing generic manufacturers to rely on innovator safety and efficacy data. Established the Paragraph IV patent certification system enabling generic manufacturers to challenge brand drug patents. Granted 180-day market exclusivity to the first ANDA filer who successfully certifies against a patent. Fundamental to the entire U.S. generic drug industry.
I
IDEIDE21 CFR Part 812Device
Investigational Device Exemption. Required before conducting significant risk (SR) device clinical studies in U.S. human subjects. The IDE is the device equivalent of the IND for drugs — it allows shipment of an unapproved device across state lines for clinical study purposes. Non-significant risk (NSR) device studies do not require an IDE application to FDA but do require IRB approval. IDE fee: ~$6,600 (FY2025).
Import AlertImport
A formal FDA notice to CBP field staff instructing them to detain products from a specific firm, product, or country-product combination without physical examination (DWPE). Import alerts represent FDA's most severe import enforcement mechanism. Key import alerts: IA 66-40 (drugs, non-current GMP), IA 16-129 (aquaculture, unapproved drug residues), IA 99-32 (food, filth/contamination), IA 45-02 (cosmetics, prohibited ingredients), IA 54-15 (devices, unregistered/no 510k).
INDIND21 CFR Part 312Drug
Investigational New Drug Application. Required before conducting clinical studies of an unapproved drug in U.S. human subjects. The IND is an exemption from the prohibition on shipping unapproved drugs across state lines for clinical use — not an approval. FDA has 30 days to place a clinical hold after IND submission; silence means the trial can proceed. Annual IND reports required throughout the clinical program.
INCIINCICosmetics
International Nomenclature of Cosmetic Ingredients. The standardized naming system required for cosmetic ingredient declarations on U.S. labels under 21 CFR § 701.3. INCI names are maintained by the Personal Care Products Council (PCPC). Using trade names, marketing names, or common names instead of INCI names on cosmetic labels is a labeling violation. Reference: ewg.org/skindeep, EU CosIng database, or cosmeticsinfo.org for INCI name lookups.
L
Label21 U.S.C. § 321(k)Labeling
The written, printed, or graphic matter on the immediate container of an article — the physical label affixed to or printed on the product or its packaging. Distinguished from the broader term 'labeling' which also includes digital content, websites, and promotional materials accompanying the product.
Labeling21 U.S.C. § 321(m)Labeling
All labels AND all other written, printed, or graphic matter upon any article or any of its containers or wrappers, or accompanying such article. Courts have interpreted this to include company websites, social media posts promoting specific products, marketplace listings (Amazon, eBay), QR code destinations, package inserts, brochures, and catalogs. Drug claims in any labeling convert the product to an unapproved drug.
M
MDRMDR21 CFR Part 803Device
Medical Device Reporting. Post-market surveillance obligation requiring device manufacturers, importers, and user facilities to report device-related deaths and serious injuries to FDA. Manufacturers must report: deaths within 30 calendar days, serious injuries within 30 calendar days, malfunctions that could cause or contribute to death or serious injury if they recur within 30 days, and imminent hazard reports within 5 work days.
MedwatchPost-Market
FDA's safety reporting program for medical products. Consumers, healthcare professionals, and manufacturers can report adverse events, product quality problems, and therapeutic failures for drugs, biologics, devices, dietary supplements, and cosmetics. Mandatory reporting for manufacturers (within specified timeframes). Voluntary reporting for healthcare professionals and consumers (Form MedWatch 3500). Reports feed FDA's post-market safety surveillance systems.
Misbranding21 U.S.C. §§ 343, 352, 362General
A product is misbranded if its labeling is false, misleading, or lacks required information. Misbranding is a strict liability offense under the FD&C Act — intent is not required for a misdemeanor conviction. Common misbranding violations: missing required label elements, wrong format, foreign language only, false claims, 'FDA Approved' for products that were never approved, making drug claims for supplements or cosmetics.
MoCRAMoCRA21 U.S.C. §§ 361–364Cosmetics
Modernization of Cosmetics Regulation Act, signed December 29, 2022. The first major overhaul of U.S. cosmetics regulation since 1938. Created for the first time: mandatory facility registration (via Cosmetics Direct), mandatory product listing, required safety substantiation records, mandatory adverse event reporting (15 business days for serious AEs), FDA mandatory recall authority for cosmetics, and authorized FDA to develop cosmetics GMP regulations.
MUMSMUMS21 U.S.C. §§ 360ccc–360ccc-2Veterinary
Minor Use/Minor Species Animal Health Act of 2004. Created incentives for developing veterinary drugs for minor species (non-major animal species) and for minor uses in major species. Benefits include: 7-year market exclusivity, conditional approval pathway (market for up to 5 years while collecting efficacy data), and grant funding. Without MUMS incentives, the market for drugs treating rare conditions in guinea pigs or ornamental fish would be too small to justify full NADA development.
N
NADANADA21 CFR Parts 514–516Veterinary
New Animal Drug Application. The primary approval pathway for new veterinary drugs. Requires demonstration of: target animal safety, human food safety (for food-producing species), environmental safety, and effectiveness. Full clinical studies in the target species required. CVM review center. Upon approval, provides permanent legal authority to market the drug. The Green Book lists all approved NADAs (equivalent to the Orange Book for human drugs).
NDANDA21 CFR Part 314Drug
New Drug Application. The approval pathway for brand-name drugs — any new drug not previously approved by FDA. Must demonstrate safety and effectiveness through full clinical trial program (Phases I, II, III) plus Chemistry, Manufacturing, and Controls (CMC) data, and proposed labeling. FDA review: 10–12 months (standard), 6 months (priority review). Application fee: ~$4.05M (FY2025). Upon approval: 5-year market exclusivity for new chemical entities.
NDC NumberNDC21 CFR § 201.2Drug
National Drug Code. A unique 10-digit identifier for every human drug product marketed in the U.S. Format: [Labeler Code]-[Product Code]-[Package Code]. Required on all drug labels and cartons. A drug marketed without an NDC number is misbranded. NDC numbers appear on pharmacy insurance claims, dispensing records, adverse event reports, and in all drug listing submissions.
NDI NotificationNDI21 U.S.C. § 350bSupplement
New Dietary Ingredient Notification. Required at least 75 days before marketing any dietary supplement containing an ingredient that was not marketed in the U.S. before October 15, 1994. The notification must include the ingredient's identity, conditions of use, and the basis for concluding it will reasonably be expected to be safe. FDA may issue an objection letter or acknowledge without objection. One of the most commonly violated DSHEA requirements.
O
Orange BookDrug
FDA's Approved Drug Products with Therapeutic Equivalence Evaluations. The authoritative reference for all approved prescription drug products. Lists all approved NDAs and ANDAs, their therapeutic equivalence ratings (A-rated = therapeutically equivalent; B-rated = not therapeutically equivalent), and associated patents (relevant for Paragraph IV ANDA strategies). The starting point for any generic drug development program. Searchable at accessdata.fda.gov/scripts/cder/ob.
OTC Monograph21 CFR Parts 310, 330Drug
A published FDA standard establishing the conditions under which certain OTC drug products can be marketed without an NDA. Each monograph specifies: permitted active ingredients and concentrations, permitted indications, required warnings, and label format. Products conforming to an applicable monograph may be marketed without FDA pre-approval. Updated under the OTC Monograph Reform Act (2020) using administrative orders rather than formal rulemaking.
OOSOOSGMP
Out-of-Specification Result. A test result that falls outside established acceptance criteria. OOS results cannot be ignored, averaged, or informally discarded — they require formal investigation per a written OOS procedure to determine whether the result represents a true product failure (laboratory assignable cause not found) or a laboratory error (assignable cause found, result may be invalidated). Improperly handled OOS results are a major data integrity concern for FDA.
P
PAIPAIInspection
Pre-Approval Inspection. Conducted by FDA's ORA before approving a new NDA, ANDA, BLA, or NADA. Verifies that the manufacturing facility's actual operations match what was described in the application. A PAI failure can delay drug approval by 12–24 months. For domestic facilities, PAIs are unannounced. For foreign facilities, FDA typically schedules PAIs with advance notice due to travel logistics. PAI outcomes directly determine whether FDA will approve the pending application.
Patent Dance42 U.S.C. § 262(l)Biologic
Informal name for the BPCIA's structured patent dispute process between biosimilar applicants and reference product sponsors. Involves sequential exchange of application information, patent lists, and positions, followed by negotiation of which patents to litigate in the 'first wave.' Can result in a 30-month automatic stay of biosimilar approval during patent litigation, plus 180-day notice of commercial marketing before launch. One of the most complex patent dispute processes in U.S. law.
PCQIPCQI21 CFR § 117.4Food
Preventive Controls Qualified Individual. A person who has successfully completed FSMA-recognized training in preventive controls for human food or animal food. Required to develop, validate, and review the Food Safety Plan for covered food facilities. PCQI training is typically a 2-day course offered by the Food Safety Preventive Controls Alliance (FSPCA) and recognized by FDA. Having a PCQI is a mandatory FSMA compliance requirement for covered facilities.
PMAPMA21 CFR Part 814Device
Premarket Approval. The most rigorous FDA device review process — required for Class III (life-sustaining or high-risk) medical devices. Unlike the 510(k) (which relies on predicate comparison), PMA requires the applicant to independently demonstrate through valid scientific evidence, typically including clinical data, that the device is safe and effective for its intended use. PMA fee: ~$450,000 (FY2025). Approved PMA devices are 'FDA-approved' — distinguished from 510(k)-cleared devices.
PREDICTPREDICTImport
Predictive Risk-based Evaluation for Dynamic Import Compliance Targeting. FDA's computer-based risk screening system that analyzes import entry data to identify shipments most likely to have compliance violations. PREDICT scores every shipment using risk factors including facility compliance history, prior refusals, import alert status, country-product risk profiles, and whether the importer has FSVP documentation. The vast majority of compliant shipments from registered, compliant facilities pass PREDICT without physical examination.
Principal Display PanelPDP21 CFR § 101.1Labeling
The part of a label most likely to be seen by consumers under normal retail display conditions. For a bottle: the front face. Required elements on the PDP: statement of identity (product name) and net quantity of contents. These elements cannot be moved to the information panel or back of the package. The net quantity must appear in the bottom 30% of the PDP area.
Prior NoticePN21 CFR § 1.280Food
Pre-import notification required for every food shipment entering the United States. Filed electronically through FDA's Prior Notice System Interface (PNSI) or through CBP's Automated Broker Interface (ABI). Timing: 2 hours before arrival (truck), 4 hours (air/rail), 8 hours (ocean). No prior notice = automatic refusal at the border with no ability to refile after the fact. The Prior Notice confirmation number must be provided to the customs broker before the shipment arrives.
Purple BookBiologic
FDA's Biological Products: Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. The biologics equivalent of the Orange Book. Lists all FDA-licensed biological products, their BLA approval dates (determining when 12-year exclusivity expires), and all approved biosimilars with their interchangeability designations. Searchable at purplebooksearch.fda.gov. Essential starting point for any biosimilar development program.
Q
Q-Sub / Pre-SubmissionQ-SubDevice
Q-Submission (formerly Pre-Submission). A free meeting or written interaction between a device manufacturer and CDRH reviewers before filing a 510(k), PMA, or De Novo application. FDA responds in writing within 75 days. Q-Subs can confirm predicate device selection, appropriate testing requirements, submission format, and FDA's general position on novel device types. The most underutilized and most valuable tool in device regulatory strategy.
QSRQSR21 CFR Part 820Device
Quality System Regulation. The GMP framework for medical device manufacturers. Unlike drug GMP, QSR includes design controls — a requirement unique to devices. Key QSR documents: Design History File (DHF), Device Master Record (DMR), Device History Record (DHR). Key QSR requirements: CAPA, purchasing controls, production controls, acceptance activities, distribution records, complaint handling, and internal audits. Being harmonized with ISO 13485 in the updated DQSR.
R
REMSREMS21 U.S.C. § 355-1Drug
Risk Evaluation and Mitigation Strategy. A required FDA drug safety program for certain drugs with serious risks that need to be managed to ensure benefits outweigh risks. Components may include: medication guides, communication plans, or Elements to Assure Safe Use (ETASU) such as restricted distribution systems requiring special certification of prescribers and dispensers. REMS are required conditions of NDA approval for certain high-risk medications.
Responsible Corporate Officer Doctrine21 U.S.C. § 333Enforcement
Legal doctrine established in United States v. Park (1975) under which a corporate officer can be convicted of a misdemeanor under the FD&C Act even without personal knowledge of the violation and without taking any deliberate act causing the violation. The standard is whether the officer had the authority and responsibility to prevent the violation. This is one of the most powerful personal liability provisions in U.S. regulatory law.
Responsible Person21 U.S.C. § 364Cosmetics
Under MoCRA, the manufacturer or distributor whose name appears on the cosmetic product label. The responsible person bears all compliance obligations under MoCRA: facility registration, product listing, safety substantiation record maintenance, and adverse event reporting. For foreign manufacturers who sell to U.S. distributors that relabel the product, the U.S. distributor typically becomes the responsible person and bears the MoCRA obligations.
S
Section 510(k)510(k)21 U.S.C. § 360(k), 21 CFR Part 807Device
Premarket Notification. The clearance pathway for most Class II medical devices. A 510(k) demonstrates that a device is 'substantially equivalent' to a legally marketed predicate device — not that it is independently safe and effective. FDA clearance means the device can be marketed, but it is FDA-cleared, NOT FDA-approved. The distinction matters for marketing communications. eSTAR format required since October 2022. Standard fee: ~$21,000 (FY2025).
SOPSOPGMP
Standard Operating Procedure. A written step-by-step document specifying how to perform a specific task in a GMP environment. SOPs must be: written and approved before being followed, current (revision-controlled and updated when the underlying process changes), accessible to all personnel who perform the task, followed exactly — deviations require documentation. The principle 'if it isn't written, it didn't happen' makes SOPs the foundation of every GMP quality system.
SPLSPLDrug
Structured Product Labeling. An FDA-required XML-based electronic format used for drug registration, drug listing, and drug labeling submissions. SPL is the technical format required for all drug establishment registrations and drug listings submitted to FDA's Drug Registration and Listing System (DRLS). Most pharmaceutical companies use regulatory affairs software (Veeva Vault, Aris Global, etc.) or third-party service providers to prepare SPL submissions.
Structure/Function Claim21 CFR § 101.93Supplement
A claim describing the role of a nutrient or dietary ingredient in affecting the structure or function of the body — without referencing a specific disease. Permitted on dietary supplement labels under DSHEA with the required disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.' Manufacturer must notify FDA within 30 days of first marketing a structure/function claim. Examples: 'Supports immune health,' 'Promotes cardiovascular function.'
Substantial Equivalence21 U.S.C. § 360c(i)Device
The legal standard for 510(k) clearance. A device is substantially equivalent to a predicate if it has the same intended use as the predicate AND the same technological characteristics, OR different technological characteristics that do not raise different questions of safety and effectiveness and the device is at least as safe and effective as the predicate. A finding of substantial equivalence does not mean FDA independently determined the device is safe and effective — it means FDA found it comparable to a legally marketed predicate.
T
Third-Party Certification (FSMA)21 CFR Part 3Food
An FSMA pathway allowing FDA-recognized accreditation bodies to accredit third-party auditors to certify foreign food facilities and their foods as meeting FDA requirements. Certification from an FDA-recognized third-party auditor reduces PREDICT risk scores and supports FSVP compliance documentation. Voluntary — but facilities with accredited certifications receive expedited import clearance and are eligible for the Voluntary Qualified Importer Program (VQIP).
U
UDIUDI21 CFR Part 830Device
Unique Device Identification. A unique numeric or alphanumeric code assigned to medical device labels per FDA's UDI Rule. Consists of a Device Identifier (DI — static, identifies the labeler and specific version/model) plus a Production Identifier (PI — dynamic, includes lot number, serial number, expiry date). Both human-readable (HRI) and machine-readable (barcode/RFID) formats required on device labels. DI must be submitted to FDA's GUDID before distribution. Non-compliant devices are misbranded.
U.S. Agent21 CFR § 1.227Registration
A person residing or maintaining a place of business in the United States who is designated by a foreign food, drug, device, or cosmetic facility to serve as FDA's point of contact for that facility. U.S. Agents must be available 24/7. They receive official FDA correspondence, relay inspection requests, and are the primary communication link between FDA and the foreign facility. Required for all foreign food facilities (under Bioterrorism Act), foreign drug establishments, foreign device establishments, and foreign cosmetic facilities under MoCRA.
V
VCPRVCPRVeterinary
Veterinarian-Client-Patient Relationship. A legal requirement for the extra-label use of approved animal drugs under AMDUCA (Animal Medicinal Drug Use Clarification Act of 1994). A valid VCPR requires: the veterinarian has sufficient knowledge of the patient through a recent examination or farm visit, the veterinarian has accepted responsibility for the health of the patient, the client (animal owner) has agreed to follow the veterinarian's instructions, and the veterinarian is available for follow-up if adverse reactions occur.
VFDVFD21 CFR Part 558Veterinary
Veterinary Feed Directive. A written statement from a licensed veterinarian authorizing a client to obtain and use a VFD drug in or on animal feed for a specific therapeutic use. VFD drugs are antibiotics and other drugs added to animal feed that require veterinary oversight — created to combat antimicrobial resistance in food-producing animals. VFD-labeled drugs cannot be purchased or used without a valid VFD from a licensed veterinarian. Feed mills must maintain VFD records.
VQIPVQIPImport
Voluntary Qualified Importer Program. An FDA program allowing U.S. food importers to pay an annual fee (~$16,000) in exchange for expedited review and automated release of food shipments. VQIP-enrolled importers must use only FDA-recognized third-party accredited auditors for all foreign suppliers, maintain continuous compliance, and meet all FSVP requirements. VQIP reduces PREDICT risk scores and accelerates customs clearance for high-volume food importers.
W
Warning LetterEnforcement
A formal written notice from FDA identifying specific regulatory violations and requesting voluntary corrective action within 15 business days. Warning Letters are public documents posted permanently on FDA's website. They are not fines or penalties but represent FDA's formal determination that violations exist. A Warning Letter triggers increased inspection frequency, may trigger import alerts, and signals that FDA will escalate to seizure, injunction, or criminal prosecution if violations are not corrected.
Withdrawal PeriodVeterinary
The minimum time that must pass between the last administration of a veterinary drug and the time when the animal or its products (meat, milk, eggs, honey) can be used for human food consumption. Required on all veterinary drug labels for food-producing species. Failure to follow withdrawal periods can result in drug residue violations, condemned meat or milk, and criminal prosecution. When a veterinarian uses a drug extra-label (under AMDUCA), they must establish an appropriately extended withdrawal period.
Z
Zero ToleranceFood/Veterinary
An FDA standard that prohibits any detectable level of a specific substance in a food or food animal product. Examples: chloramphenicol in all food-producing animals (zero tolerance for any detectable level), nitrofurans in aquaculture, certain color additives in foods (not approved = any level is a violation). Zero tolerance substances differ from substances with established maximum residue limits or action levels — for zero tolerance substances, any confirmed detection triggers refusal or seizure.
No terms match your search. Try a different keyword or abbreviation.